ImmunoGen, Inc. (IMGN) Financials

NASDAQ:IMGN

Market Cap

3.90B

Total Revenue

108.78M

Gross Profit

108.61M

Operating Income

-220.89M

Net Income

-222.93M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	35,535,000	59,896,000	85,541,000	60,002,000	115,447,000	53,816,000	82,271,000	132,299,000	69,856,000	108,782,000
costOfRevenue	87,073,000	106,958,000	111,768,000	146,915,000	139,739,000	173,886,000	114,522,000	114,592,000	--	176,000
grossProfit	-51,538,000	-47,062,000	-26,227,000	-86,913,000	-24,292,000	-120,070,000	-32,251,000	17,707,000	69,856,000	108,606,000
researchAndDevelopmentExpenses	87,073,000	106,958,000	111,768,000	146,915,000	139,739,000	173,886,000	114,522,000	114,592,000	151,117,000	213,370,000
sellingAndMarketingExpenses	--	--	--	--	--	--	--	--	--	--
generalAndAdministrativeExpenses	21,471,000	24,469,000	28,228,000	36,916,000	33,911,000	36,716,000	38,489,000	38,600,000	43,812,000	--
sellingGeneralAndAdministrativeExpenses	21,471,000	24,469,000	28,228,000	36,916,000	33,911,000	36,716,000	38,489,000	38,600,000	43,812,000	116,129,000
operatingExpenses	108,544,000	131,427,000	139,996,000	183,831,000	173,650,000	210,602,000	153,011,000	153,192,000	194,929,000	329,499,000
operatingIncome	-73,009,000	-71,531,000	-54,455,000	-123,829,000	-58,982,000	-160,479,000	-92,173,000	-135,485,000	-125,073,000	-220,893,000
totalOtherIncomeExpensesNet	198,000	167,000	-848,000	304,000	-21,087,000	-361,000	-11,960,000	91,113,000	-14,230,000	-818,000
ebitda	-73,009,000	-71,531,000	-55,303,000	-123,525,000	-55,596,000	-153,454,000	-65,726,000	-19,683,000	-126,153,000	-217,546,000
depreciationAndAmortization	4,641,000	4,598,000	5,513,000	5,327,000	5,963,000	7,411,000	26,447,000	115,802,000	-1,080,000	3,347,000
interestIncome	--	--	--	--	--	--	--	--	--	--
interestExpense	-198,000	-167,000	5,436,000	20,130,000	16,722,000	10,726,000	16,974,000	23,202,000	13,150,000	4,165,000
incomeBeforeTax	-72,811,000	-71,364,000	-60,739,000	-143,655,000	-96,012,000	-167,873,000	-104,133,000	-44,372,000	-139,303,000	-221,711,000
incomeTaxExpense	-198,000	-167,000	6,284,000	19,826,000	37,030,000	7,394,000	17,960,000	22,311,000	10,053,000	1,218,000
netIncome	-72,811,000	-71,364,000	-60,739,000	-143,655,000	-96,012,000	-167,873,000	-122,093,000	-66,683,000	-149,356,000	-222,929,000
eps	-0.87	-0.83	-0.71	-1.65	-0.98	-1.2	-0.82	-0.38	-0.72	-0.88
epsdiluted	-0.87	-0.83	-0.71	-1.65	-0.98	-1.2	-0.82	-0.38	-0.72	-0.88
weightedAverageShsOut	84,063,000	85,481,000	86,038,000	86,976,000	98,068,000	139,946,000	148,311,000	176,153,000	206,147,000	253,631,000
weightedAverageShsOutDil	84,063,000	85,481,000	86,038,000	86,976,000	98,068,000	139,946,000	148,311,000	176,153,000	206,147,000	253,631,000
costAndExpenses	108,544,000	131,427,000	139,996,000	183,831,000	173,650,000	210,602,000	153,011,000	153,192,000	194,929,000	329,675,000
otherExpenses	198,000	167,000	-848,000	304,000	2,607,000	3,332,000	5,014,000	1,210,000	-1,080,000	3,347,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Waltham, MA, US

Website

immunogen.com

CEO

Mr. Mark Joseph Enyedy

Employees

277

About the Company

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.